Physician profile
Cecil C Bailey
NPI 1871546598
$2,966.08
in general payments reported to CMS, 2019-2025
27 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $303 · 2021: $297 · 2022: $305 · 2023: $559 · 2024: $373 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $651.92 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $460.30 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $341.85 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $320.99 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.92 | 2023-2025 | Jardiance |
| Acera Surgical, INC. | $164.96 | 2025 | Restrata Wound Matrix |
| Lupin INC. | $142.95 | 2019-2020 | |
| Abbvie INC. | $97.35 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $95.12 | 2024-2025 | Breztri, Airsupra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.61 | 2021-2022 | |
| Astellas Pharma US INC | $39.52 | 2024 | Veozah |
| Amgen INC. | $37.04 | 2025 | Repatha |
| Corcept Therapeutics | $36.91 | 2025 | Korlym |
| Abbott Laboratories | $33.60 | 2022-2023 | Freestyle Libre 2 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.35 | 2022-2023 | Xifaxan |
| Exact Sciences Corporation | $31.51 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $27.78 | 2025 | Austedo Xr |
| Gilead Sciences, INC. | $25.15 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.67 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.60 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.04 | 2021 | |
| Sumitomo Pharma America, INC. | $15.02 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $14.71 | 2022 | |
| Allergan, INC. | $13.89 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.31 | 2021 | |
| Kyowa Kirin, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecil Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.